Assessment of vitamin $B_{12}$ tissue stores in elderly proton pump inhibitor users

Judith M. Lukaszuk1*, David A. Walker2, Masih Shokrani1, Josephine Umoren1 and Eric J. Norman3

Abstract: Background: Adults over the age of 65 years are more prone to gastro-esophageal reflux and, as such, are commonly prescribed proton pump inhibitors (PPIs). PPIs inhibit gastric acid secretion which can have adverse effects on vitamin $B_{12}$ absorption. This quasi-experimental study was conducted to determine whether chronic use ($\geq 1$ year) of proton pump inhibitors (PPIs) results in decreased vitamin $B_{12}$ levels in adults aged 68–94 years, as indicated by increased urinary methylmalonic acid (uM-MA).

Methods: Fifteen men and women who had been using PPIs daily for a minimum of one year were recruited. Fifteen subjects not using PPIs were age (±3 years) and gender matched to the subjects taking PPIs. Tissue stores of vitamin $B_{12}$ were determined using uM-MA.

Results: The majority of subjects in this study resided in assisted care living facilities (55.66%) and the remaining subjects (43.33%) were free living. There were no significant differences in uM-MA levels between those using PPIs (Mdn = 1.1 μg uM-MA/mg creatinine), and those not using PPIs (Mdn = 1.1 μg uM-MA/mg creatinine) ($p = 0.75$).

Conclusion: Chronic use of PPIs did not alter vitamin $B_{12}$ status in healthy individuals aged 68–94 years. Larger studies are indicated to validate these findings.

Subjects: Nutrition; Pharmacology; Nutrition and Dietetics

Keywords: urinary methylmalonic acid; vitamin B12 deficiency; elderly; proton pump inhibitors

ABOUT THE AUTHOR

Judith M. Lukaszuk, is a professor in Nutrition in the School of Health Studies at Northern Illinois University in DeKalb, Illinois, USA. She has been teaching for 18 years and lecturing nationally on micronutrient metabolism as well as integrative nutrition. The main focus of her research includes vitamin and mineral metabolism and nutrition supplements used to enhance exercise performance. This article is the third in a series looking at the effects of PPIs usage on Vitamin $B_{12}$ levels across the lifespan.

PUBLIC INTEREST STATEMENT

The purpose was to determine whether chronic use of antacid medication called “proton pump inhibitors” (PPIs) resulted in a vitamin $B_{12}$ deficiency as measured by urinary methylmalonic acid (uM-MA) levels in elderly aged 68–94 years old. In order for Vitamin $B_{12}$ to be absorbed, gastric acid is required. The use of PPIs limits gastric acid in the stomach, and the absorption of vitamin $B_{12}$ may be severely impaired. Fifteen men and women who had been taking PPIs daily for a minimum of one year were age (±3 years) and gender matched to subjects not taking PPIs. There were no significant differences in uM-MA levels between those taking PPIs and those not taking PPIs ($p = 0.75$). Chronic use of PPIs ($\geq 2$ years) did not alter vitamin $B_{12}$ status in healthy individuals aged 68–94 years.
1. Introduction
In the United States, adults over 65 years of age comprise 15.2% of the population, or 48 million people (United States Census Bureau, 2017). This is a 36% increase since 2000, and more than a tripling of the size of the older adult population since 1900 (United States Census Bureau, 2017). Adults over the age of 65 years are more prone to developing gastroesophageal reflux disease (GERD) and, as such, are commonly prescribed proton pump inhibitors (PPIs) for long-term use (Achem & DeVault, 2014). PPIs act by binding the H+K+ ATPase pump of the parietal cells, thereby, inhibiting gastric acid secretion from these cells in the stomach (Yang & Metz, 2010). The resulting lack of gastric acid is thought to have adverse effects on the absorption of vitamin B₁₂ bound to protein in food sources. Gastric acid activates protease enzymes, such as pepsin, which break down protein and free the B₁₂ bound to protein (Yang & Metz, 2010). The free vitamin B₁₂ is then available for absorption. Elderly adults are prone to additional gastric problems which also may decrease their ability to absorb nutrients so those undergoing PPI treatment may be at ever greater risk for nutrient deficiencies (Masclee, Sturkenboom, & Kuipers, 2014). The adverse effects of PPIs have been reported, but studies often are inconclusive, and the long-term effects of PPI treatment remain largely unknown (Abraham, 2012; Dharmarajan, Kanagala, Murakonda, Lebelt, & Norkus, 2008; Hirschowitz, Worthington, & Mohnen, 2008; Ito & Jensen, 2010; Masclee et al., 2014; Rozgony, Fang, & Kuczmarski, 2010; Saltzman et al., 1994; Valuck & Ruscin, 2004; Yang & Metz, 2010).

When vitamin B₁₂ tissue stores decrease to a level of deficiency, irreversible neurological damage, cognitive impairment, and dementia can result (Grober, Kisters, & Schmidt, 2013). In addition, vitamin B₁₂ malabsorption may be further exacerbated by age-related gastric changes (i.e. hypochlorhydria) in the elderly adult population (Wolters, Strohle, & Hahn, 2004). Cognitive function in older adults is important and it may be markedly improved by providing a vitamin B₁₂ supplement, should low levels be detected. Unlike serum vitamin B₁₂ levels, which have limited specificity and sensitivity for detecting tissue deficiency, uM-MA is specific to tissue stores of vitamin B₁₂ (Matchar et al., 1987).

The purpose of this study was to determine the effect of PPIs on vitamin B₁₂ tissue stores as measured by uM-MA in elderly adults aged 68–94 years.

2. Methods

2.1. Participants
A quasi-experimental design was used for this study. Thirty men and women were recruited from April to August 2016 using informational flyers posted in local assisted living facilities, churches, and recreational facilities. Prior to participating in the study, all subjects signed a consent form. All study procedures were approved by the Institutional Review Board at Northern Illinois University DeKalb, IL. Fifteen subjects who had been taking PPIs daily for a minimum of one year were recruited first. Fifteen subjects in the control group, not taking PPIs were age (±3 years) and gender matched to subjects in the PPI group. Subjects were excluded if they had a history of Crohn’s disease, ulcerative colitis, pernicious anemia, use of Metformin, liver disease, kidney disease (due to potential malabsorption of vitamin B₁₂), adherence to a vegan diet (due to insufficient intake of vitamin B₁₂), taking intramuscular shots of vitamin B₁₂, or taking nasal Nascobal (both of which bypass digestion and may elevate vitamin B₁₂ levels) (Strativa Pharmaceuticals, Spring Valley, NY).

2.2. Data collection

2.2.1. Survey questionnaire
Each subject completed a survey questionnaire designed to collect details about demographics, use of multivitamin supplements, B vitamin supplements, and use and name of PPIs.

2.3. Diet analyses
Diet analyses were performed on 3-day food logs provided by the participants. Nutrition Calc plus (version 3.5 McGraw-Hill Companies, Columbus, OH) was utilized for assessment of the 3-day food logs. All data were computed by the same investigator on the research team to minimize any
variance. Analyses of the following sample characteristics were performed: total kcal/kg, fat, protein, and carbohydrate as percentages of total kcal/kg, and dietary B12, vitamin B6, and folic acid.

2.4. Anthropometrics
Researchers collected data at the following sites: at the individual’s local assisted living residences, churches, and recreational facilities. Anthropometric measurements were taken in lightweight clothing and bare feet. Height was measured using a tape measure while subjects placed their heels, buttocks, and head against a wall. Weight, fat mass, body fat percent, lean body mass, and body mass index (BMI) were assessed using a bioelectrical impedance scale (Tanita body composition Analyzer TBF-300A, Arlington Heights, IL). BMIs were calculated by the Tanita analyzer using the standard equation (kilogram per meter squared). Urine samples were collected in sterile containers and were transferred into vials containing 5 mg of thymol as a preservative, which allowed samples to be mailed unrefrigerated. The vials were stored at −20°C until all data had been collected. The samples were then shipped overnight for analysis to Norman Clinical Laboratory, Inc. (NCL) in Lexington, KY.

2.5. Laboratory measurements
The samples were analyzed for uM-MA by NCL at their laboratory facility located in Lexington, KY. Measurement of uM-MA levels of the urine samples were determined using LC/MS/MS.13A. The method was performed by using a Shimadzu Nexera XR HPLC system coupled with a Sciex 4500MD mass spectrometer operated in the ESI mode (capillary voltage—4,500 volts). Standards were purchased from Cerilliant, MMA (1 mg/ml) P/N MK-080 and MMA-d3 (1 mg/ml), P/N M-105. Three calibrators (20, 5,000, 20,000 ng/ml) and two quality controls (500, 10,000 ng/ml) were prepared by dilution of the Cerilliant MMA standards in deionized water. The internal standard spiking solution was prepared by adding 10 μL MMA-d3 (1 mg/mL) to 40 mL of deionized water. For analysis, 50 μL of internal standard spiking solution and 200 μL of deionized water were added to 50 μL of each sample, calibrator and quality control solution in a 96-well plate. The specimens then were centrifuged at 4,000 RPM for 20 min. The 96-well plates then were placed on an autosampler rack and 2 μL of each specimen was injected into the HPLC for analysis.

The column used was a Phenomenex Synergi Hydro-RP, 2.5 um, 3.0 × 100 mm (P/N 00B-4387-YO). Mobile phase B was 0.1% formic acid in acetonitrile and mobile phase A is 0.1% formic acid in water. The column was held at 40°C, with a stepwise gradient as follows: Start at 0% B and go to 18% B at 1.8 min; proceed to 95% B at 1.9 min, maintain at 95% until 2.5 min; return to 0% B. The total run time per sample was 4.5 min including equilibration. The scheduled multiple reaction monitoring (MRM) table (ESI positive) is shown below:

| Q1 Mass | Q3 Mass | Dwell (ms) | Analyte   | DP  | CE  | CXP |
|---------|---------|------------|-----------|-----|-----|-----|
| 117.0   | 72.9    | 40         | MMA 1     | −30 | −13 | −10 |
| 117.0   | 54.9    | 40         | MMA 2     | −30 | −34 | −10 |
| 120.0   | 75.9    | 40         | MMA-d3    | −30 | −13 | −10 |

All LC/MS/MS data were processed using MultiQuant software version 3.0 (Wolters et al., 2004).

For the data analysis, levels of uM-MA were considered to be normal if they were <3.8 μg MMA/mg creatinine or <3.6 mmol/mol creatinine (Norman & Morrison, 1993).

2.6. Statistical analysis
Due to the small sample size and the matched pairs design, this study used the non-parametric related-samples Wilcoxon signed rank test procedure (Harris, Boushey, Bruemmer, & Archer, 2008) tested the hypothesis that subjects using PPIs would have higher uM-MA levels than their age matched and gender matched controls not using PPIs, indicating vitamin B12 deficiency in PPI users.
This test also determined differences between the PPI group and the non-PPI group on anthropometrics and diet/supplement intake variables (Table 1).

The mean (M) and standard deviation (SD) were determined for each key variable between the PPI group and non-PPI group as M ± SD. The median (Mdn) was also provided for each key variable. The tests for equivalency between key variables of each group were provided as a Z-value. The testing of the hypothesis was also reported as a Z-value. Statistical significance for all data analyses were accepted at the alpha level of $p < 0.05$. Data were analyzed using the Statistical Package for Social Sciences (SPSS) for Windows (Version 23.0, 2015, SPSS, Inc, Chicago, IL).

### 3. Results

#### 3.1. Participants

Participants ranged in age from 68 to 94 years, with a mean age of 80.17 years. Participants were age matched (±3 years) and gender matched. Six males and 24 females participated in the study. Most participants in both groups were Caucasian 96.6% ($n = 29$); while one PPI user was Hispanic.
3.1.1. Details regarding PPI use
The PPI group had been taking PPIs for 2–15 years, with a mean of 6.7 years $M \pm SD = 6.7 \pm 3.6$, Mdn = 6.0. From the PPI group, 12 participants reported taking over-the-counter PPIs (80%, $n = 12$) ($n = 8$ Omeprazole; $n = 4$ Pantoprazole), while 3 participants were taking prescription PPIs (20%, $n = 3$) ($n = 2$ Protonix; $n = 1$ Nexium). Fourteen PPI users reported acid reflux or GERD as the reason for the prescription of the PPI. The remaining PPI user reported use of PPIs for Barrett’s esophagus.

3.2. Equivalency of groups

3.2.1. Anthropometrics
The PPI group and non-PPI group were tested for equivalency using the related-samples Wilcoxon signed rank test. The PPI group and non-PPI group were significantly different on BMI ($Z = -2.78$, $p = 0.005$), body fat percent ($Z = -2.44$, $p = 0.015$), and body fat mass ($Z = -2.67$, $p = 0.008$). That is, the PPI group had a higher BMI, body fat percent, and body fat mass. The groups were not significantly different for lean body mass ($Z = -0.97$, $p = 0.334$) (Table 1).

3.2.2. Diet intake
Diet intake data were not available for two PPI participants and one non-PPI participant; therefore, the data presented for diet intake reflects the related-samples Wilcoxon signed rank test using $n = 27$ instead of 30 as was previously conducted with the full data-set. Diet intake descriptive values were calculated with 27 participants and equivalency of groups regarding diet intake was analyzed using 13 rather than 15 pairs. Wilcoxon tests for equivalency of groups indicated that there were no statistically significant differences between average daily caloric intake (kcal/kg) ($Z = -0.94$, $p = 0.347$), carbohydrates as percentage of caloric intake ($Z = -0.76$, $p = 0.449$), protein as percentage of caloric intake ($Z = -0.71$, $p = 0.477$), fat as percentage of caloric intake ($Z = -1.73$, $p = 0.084$), dietary vitamin B$_{12}$ (μg) ($Z = -1.57$, $p = 0.117$), dietary vitamin B$_{6}$ (mg) ($Z = -0.71$, $p = 0.477$), and dietary folate (μg) ($Z = -0.39$, $p = 0.695$) (Table 1).

3.2.3. Supplement intake
Eight PPI users reported no multivitamin use, while the remaining PPI users consumed a multivitamin with vitamin B$_{12}$, vitamin B$_{6}$, and folic acid with one PPI user taking a super vitamin B-complex daily. Ten non-PPI users reported using no multivitamins while the remaining five non-PPI users consumed a multivitamin daily.

Wilcoxon tests for equivalency of groups regarding supplement intake indicated that there were no statistically significant differences between supplemental vitamin B$_{12}$ (μg) ($Z = -0.287$, $p = 0.774$), supplemental vitamin B$_{6}$ (mg) ($Z = -1.532$, $p = 0.125$), and supplemental folic acid (μg) ($Z = -1.562$, $p = 0.118$) (Table 1).

3.3. Hypothesis testing
Values for uM-MA among the PPI and non-PPI group can be found in Table 2. The hypothesis that the PPI group would have higher uM-MA levels than their gender and age matched controls, indicating vitamin B12 deficiency, was not supported ($Z = -0.42$, $p = 0.967$) (Table 3).

### Table 2. Observed uM-MA for PPI group and non-PPI group

|                      | PPI group ($n = 15$) | Non-PPI group ($n = 15$) | Z score | p-value |
|----------------------|----------------------|--------------------------|---------|---------|
| uM-MA levels (μg/mg creatinine) | 1.1 ± 0.29 | 1.3 ± 0.91 | -0.42 | 0.967 |

Note: Values are means ± SD.
4. Discussion

This study showed that PPI use for an average of 6.7 years among those 68–94 years did not deleteriously affect vitamin B₁₂ tissue stores as measured by uM-MA levels. These findings concur with a 2008 study of 125 community living elderly over the age of 65 years who had been using PPIs for three years in that serum vitamin B₁₂ levels were not deleteriously affected (Den Elzen et al., 2008). The results of this study also are consistent with two previous studies by Lukaszuk et al., which evaluated uM-MA levels in two younger groups aged: 22–50 years and 50–70 years. Both studies showed that chronic use of PPIs did not affect uM-MA levels (Lukaszuk, Prawitz, Shokrani, Umoren, & Norman, 2013; Lukaszuk, Umoren, Warner, Shokrani, & Norman, 2015).

In direct contrast, three other studies showed that PPI use negatively affected serum vitamin B₁₂ status (Dharmarajan et al., 2008; Lam, Schneider, Zhao, & Corley, 2013; Valuck & Ruscin, 2004). Lam et al. (2013) conducted a large population-based study matching 25,956 individuals diagnosed with a B₁₂ deficiency to patients without a B₁₂ deficiency based on geographical residence, age (±1 year), gender, and race/ethnicity. Results indicated that those at greatest risk of B₁₂ deficiency were > 60 years of age; taking PPIs for two or more years and taking the highest mean daily dose (>1.5 PPI pills/day) (Lam et al., 2013). The similarities between the Lam et al. (2013) study and the current one is that everyone was > 60 years old and had been taking PPIs for more than two years and most subjects were taking > 1.5 PPI pills/day. It is difficult to do a direct comparison on PPI doses with the Lam et al. (2013) study and this study. Lam et al. (2013) quantified the PPI dose by the number of PPI pills taken per day, but did not specify the dosage per day. In the current study, 80% of the subjects were taking > 1.5 PPI pills per day. More specifically, 73% subjects were taking 40 mg/day of a PPI and 27% were taking 20 mg/day. The difference in findings between the Lam et al. (2013) study and this current study may have been due to differences in the total dose of PPIs taken per day and the difference in the sample sizes of the two studies.

Dharmarajan et al. (2008) examined serum vitamin B₁₂ levels and use of PPIs in 542 older adults ages 60–102 years over a duration of six years. Their results indicated that low/marginal serum vitamin B₁₂ status was observed in older adults PPI users with 19.9% in the nursing home population and 29.2% in the community living population. The authors concluded that deficiency is indeed common among the older adult population, and that more attention may be indicated to monitor vitamin B₁₂ levels in older adults using PPIs.

Lastly, a case-control study, (Valuck & Ruscin, 2004) investigated the association between vitamin B₁₂ deficiency and use of PPIs in adults aged 65 or older. Inclusion criteria included ≥65 years old and a documented serum vitamin B₁₂ measurement. The data were obtained through a university-based, geriatric, primary care facility’s medical records. Fifty-three people met the criteria for the vitamin B₁₂ deficient group and a set of controls were matched for gender and ± 1 year of age (Valuck & Ruscin, 2004). Chronic use of PPIs was defined as greater than 12 months. Findings indicated that chronic use of PPIs was associated with significantly increased risk of vitamin B₁₂ deficiency. Dharmarajan et al. (2008) and Valuck and Ruscin (2004), recommended screening of elderly individuals for vitamin B₁₂ deficiency after chronic PPI use of 3–4 years to reduce complications due to untreated vitamin B₁₂ deficiency (Dharmarajan et al., 2008; Valuck & Ruscin, 2004).

### Table 3. Observed uM-MA for PPI group and Non-PPI group by gender

| Variable                  | PPI group                                    | Non-PPI group                                |
|---------------------------|----------------------------------------------|----------------------------------------------|
|                           | Female (n = 12)                              | Female (n = 12)                              |
|                           | Male (n = 3)                                 | Male (n = 3)                                 |
| uM-MA (μg/mg creatinine)  | Mean ± SD 1.06 ± 0.26 1.33 ± 0.35 1.3        | Mean ± SD 1.31 ± 1.00 1.29 ± 0.48 1.2        |
|                           | Median 1.0 1.3 1.3 1.0 1.2                  | Median 1.2 1.2                               |

Notes: Values are means ± standard deviation (M ± SD), Median (Mdn).
Previous studies have shown that as people get older, incidence of vitamin B₁₂ deficiency increases because of a decreased ability to release protein-bound dietary vitamin B₁₂ for absorption. This is attributed to the prevalence of atrophic gastritis seen with associated with advanced age (Baik & Russell, 1999; Carmel, 1997; Russell, 2001). Valuck and Ruscin (2004) has suggested that people with atrophic gastritis resulting in achlorhydria would be unlikely to be using PPIs for acid reflux, but no studies were found to support this. Achlorhydia results from destruction of the parietal cells in the stomach which release not only the hydrochloric acid (HCl) needed to free the dietary protein-bound vitamin B₁₂, it also releases the intrinsic factor (IF) needed for absorption of the free vitamin B₁₂ (Rozgony et al., 2010). In addition to achlorhydia’s effect on vitamin B₁₂ absorption, lack of HCl affects protein digestion in the stomach by impeding pepsin activation, leading to an increase in intra-abdominal pressure. High intra-abdominal pressure opens up the cardiac sphincter resulting in gastric reflux. In the current study, participants were not assessed for atrophic gastritis.

4.1. Physical characteristics
In the current study, the PPI group was significantly different from the PPI group regarding BMI, body fat percent, and body fat mass, with the PPI group displaying a higher BMI, body fat percent, and body fat mass than the non-PPI group. The BMI of the PPI group M ± SD = 30.1 ± 3.7, Mdn = 29.3 is considered obese while the BMI of the non-PPI group M ± SD = 27.4 ± 4.4, Mdn = 26.6 is considered overweight (World Health Organization, 2017). This study as well as previous studies (Corley & Kubo, 2006; El-Serag, 2008; El-Serag, Graham, Satia, & Rabeneck, 2005; Hajar, Castell, Ghomrawi, Rackett, & Hila, 2012; Wu, Mui, Cheung, Chan, & Jao-Yiu Sung, 2007), have indicated that subjects with a higher BMI are more likely to have acid reflux and thus more likely rely on PPIs, either over-the-counter or prescribed. It is important, then that medical providers monitor PPI use and vitamin B₁₂ levels in patients with higher BMIs.

4.2. Dietary and supplement intake
The PPI group and non-PPI groups in the current study were not significantly different on dietary or supplemental intake of vitamins B₁₂, B₆ and folic acid. When dietary and supplemental intakes were combined, the recommended daily allowances (RDAs) for vitamin B₁₂, vitamin B₆, and folic acid were met. The only vitamin that would affect the uM-MA level was vitamin B₁₂ and all subjects were ingesting a sufficient amount of vitamin B₁₂, and all subjects based on the established RDA. This indicates that if a difference in uM-MA had been detected, it would likely have been due to the use of PPIs.

4.3. Urinary methylmalonic acid
The use of uM-MA as an accurate biomarker of vitamin B₁₂ status, has been confirmed by previous studies, (Hill et al., 2013; Norman, 2004; Norman & Morrison, 1993). The use of uM-MA to measure vitamin B₁₂ status in PPI users was found in only two previous studies, both conducted by Lukaszuk et al. (2013, 2015). In 2013, Lukaszuk et al., investigated the effect of PPI use on vitamin B₁₂ tissue stores in 22–50 year olds, and in 2015, they repeated the study with 50–70 year olds. The current study of elderly adults, along with the two previous studies of younger age groups, found that uM-MA was not significantly different for the PPI and the non-PPI groups. These three studies, although small in size, all implemented uM-MA tests rather than serum B₁₂ tests to indicate B₁₂ levels. All three studies using uM-MA tests found no differences in the tissue stores of vitamin B₁₂ in PPI users and non-users. Larger studies utilizing the uM-MA technique are indicated to confirm these results. A large comparison study of serum B₁₂ and uM-MA tests in larger dose PPI users would be useful.

The current research was limited by the small sample size (n = 30). Due to the small sample size, a non-parametric test was utilized, which is not as powerful as a parametric test such as the paired samples t-test. Although newer statistical research has shown the justification for using the t-test in small sample sizes, the variable being tested is required to be normally distributed (deWinter, 2013). This was not the case with the uM-MA levels among PPI users and non-PPI users’ thus eliminating the ability to use a parametric test.
The PPI and non-PPI groups were also significantly different regarding three physical characteristics. The groups were significantly different on BMI, body fat percent, and body fat mass. Ideally, the groups would have been equivalent on all characteristics. Although the ages of participants were not significantly different between the PPI group and the non-PPI group, the groups were gender and age-matched within ± 3 years. Ideally, participants would be age-matched to the same age, but due to difficulty recruiting participants, this was not feasible and the researchers determined it was appropriate to age match as closely as possible.

Author contributions
The author’s responsibilities were as follows: JML was the principle investigator and was responsible for the conceptualization of the study, study design, data collection and writing the initial draft of the manuscript. DAW was responsible for the statistical analyses, interpretation of the data and editing of the manuscript. MS, JU and EJN were responsible for manuscript editing. All authors have approved the final manuscript.

Acknowledgements
We also would like to thank Bill Heckle, PhD, and Adam Clause, BS, from Lexar Labs for their assistance in methodology development and in editing the uM-MA analysis paragraph in the methods section for accuracy and clarity.

Funding
The authors received no direct funding for this research.

Competing Interests
The authors declare no competing interest.

Author details
Judith M. Lukaszuk1
E-mail: jmlukaszuk@niu.edu
David A. Walker2
E-mail: dawalker@niu.edu
Masih Shokrani3
E-mail: mshokrani@niu.edu
Josephine Umoren1
E-mail: jum1@niu.edu
Eric J. Norman4
E-mail: b12tester@aol.com
1 College of Health & Human Sciences, Northern Illinois University, DeKalb, IL 60115, USA.
2 College of Education, Northern Illinois University, DeKalb, IL 60115, USA.
3 Norman Clinical Laboratory, Inc., Cincinnati, OH 45231, USA.

Citation information
Cite this article as: Assessment of vitamin B12 tissue stores in elderly proton pump inhibitor users, Judith M. Lukaszuk, David A. Walker, Masih Shokrani, Josephine Umoren & Eric J. Norman, Cogent Medicine (2017), 4: 1389639.

References
Abraham, N. S. (2012). Proton pump inhibitors: Potential adverse effects. Current Opinion in Gastroenterology, 28, 615–620. doi:10.1097/MOG.0b013e328358d5b9
Achm, S. P., & DeVault, K. R. (2014). Gastroesophageal reflux disease and the elderly. Gastroenterology Clinics of North America, 43, 147–160. doi:10.1016/j.gtc.2013.11.004
Baik, H. W., & Russell, R. M. (1999). Vitamin B12 deficiency in the elderly. Annual Review of Nutrition, 19, 357–377. doi:10.1146/annurev.nutr.19.1.357
Carmel, R. (1997). Cobalamin, the stomach and aging. American Journal of Clinical Nutrition, 66, 750–759.
Corley, D. A., & Kubo, A. (2006). Body mass index and gastroesophageal reflux disease: A systematic review and meta-analysis. American Journal of Gastroenterology, 108, 2619–2628. doi:10.1111/j.1572-0241.2006.00849.x
Den Elzen, W. P. J., Greeneveld, Y., De Brujger, W., Sessouf, J. H. M., Le Cessie, S., Assendelft, W. J. J., & Gussekloo, J. (2008). Long-term use of proton pump inhibitors and vitamin B12 status in elderly individuals. Alimentary Pharmacology & Therapeutics, 27, 491–497. doi:10.1111/j.1365-2036.2008.03610.x
deWinter, J. C. F. (2013). Using the student’s t-test with extremely small sample sizes. Practical Assessment Research & Evaluation, 18, 1–12.
Dharmarajan, T. S., Kanagala, M. R., Mukondo, P., Lebelt, A. S., & Norkus, E. P. (2008). Do acid-lowering agents affect vitamin B12 status in older adults? Journal of the American Medical Directors Association, 9, 162–167. doi:10.1016/j.jamda.2007.10.004
El-Serag, H. (2008). The association between obesity and GERD: A review of the epidemiological evidence. Digestive Diseases and Sciences, 53, 2307–2312. doi:10.1007/s11894-008-0413-9
El-Serag, H. B., Graham, D. Y., Satia, J. A., & Rabeneck, L. (2005). Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. The American Journal of Gastroenterology, 100, 1243–1250. doi:10.1111/j.1572-0241.2005.41703.x
Grober, U., Kisters, K., & Schmidt, J. (2013). Neuroenhancement with vitamin B12-underestimated neurological significance. Nutrients, 5, 5031–5045. doi:10.3390/nu5125031
Hojar, N., Castell, D. O., Ghomrawi, H., Rackett, R., & Hila, A. (2012). Impedance pH confirms the relationship between GERD and BMI. Digestive Diseases and Sciences, 57, 1875–1879. doi:10.1007/s10620-012-2131-6
Harris, J. E., Boushey, C., Bruemmer, B., & Archer, S. L. (2008). Publishing research nutrition: A review of nonparametric methods, part 3. Journal of the American Dietetic Association, 108, 1489–1496. doi:10.1016/j.jada.2008.06.426
Hill, M. H., Flotley, J. E., Barker, M. E., Garner, C. C., Manning, N. J., Olpin, S. E., ... Powers, H. J. (2013). A vitamin B12 supplement of 500 μg/d for eight weeks does not normalize urinary methylmalonic acid or other biomarkers of vitamin B12 status in elderly people with moderately poor vitamin B-12 status. The Journal of Nutrition, 143, 142–147. doi:10.3945/jn.112.169193
Hirschowitz, B. I., Worthington, J., & Mohnen, J. (2008). Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors. Alimentary Pharmacology & Therapeutics, 27, 1110–1121. doi:10.1111/j.1365-2036.2008.03668.x
Ito, T., & Jensen, R. T. (2010). Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium. Current Gastroenterology Reports, 12, 448–457. doi:10.1007/s11894-010-0141-0
Lam, J. R., Schneider, J. L., Zhao, W., & Corley, D. A. (2013). Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA, 310, 2435–2442. doi:10.1001/jama.2013.280490
Lukaszuk, J. M., Prawitz, A. D., Shokrani, M., Umoren, J., & Norman, E. (2013). Methylmalonic acid levels in non-elderly adult chronic PPI users. American Journal of Gastroenterology, 108, 2435–2442. doi:10.1001/jama.2013.280490
Lukaszuk, J. M., Umoren, J., Warner, T. S., Shokrani, M., & Norman, E. (2015). Assessment of urinary methylmalonic acid levels in older adults on proton pump inhibitors. EC Nutrition, 2, 259–266.
Masclée, G. M. C., Sturkenboom, M. C. J. M., & Kuipers, E. J. (2014). A benefit-risk assessment of the use of proton pump inhibitors in the elderly. Drugs & Aging, 31, 263–282. doi:10.1007/s40266-014-0166-4

Matchar, D. B., Feussner, J. R., Millington, D. S., Wilkinson, D. S., Watson, D. J., & Gale, D. (1987). Isotope-dilution assay for urinary methylmalonic acid in the diagnosis of vitamin B12 deficiency. A prospective clinical evaluation. Annals of Internal Medicine, 106, 707–710. doi:10.7263/0003-4819-106-5-707

Norman, E. J. (2004). Urinary methylmalonic acid test may have greater value than the total homocysteine assay for screening elderly individuals for cobalamin deficiency. Clinical Chemistry, 50, 1482–1483. doi:10.1373/clinchem.2004.035790

Norman, E., & Morrison, J. (1993). Screening elderly populations for cobalamin (vitamin B12) deficiency using the urinary methylmalonic acid assay by gas chromatography mass spectrometry. The American Journal of Medicine, 94, 589–594. doi:10.1016/0002-9343(93)90209-8

Rozgony, N. R., Fang, C., & Kuczmarski, M. F. (2010). Vitamin B12 deficiency is linked with long-term use of proton pump inhibitors in institutionalized older adults: Could a cyanocobalamin nasal spray be beneficial. Journal of Nutrition for the Elderly, 29, 87–99. doi:10.1080/01639360903574734

Russell, R. M. (2001). Factors in aging that effect the bioavailability of nutrients. The Journal of Nutrition, 131, 1359S–1361S.

Saltzman, J. R., Kemp, J. A., Golner, B. B., Pedrosa, M. C., Dallal, G. E., & Russell, R. M. (1994). Effect of hypochlorhydria due to omeprazole treatment or atrophic gastritis on protein-based vitamin B12 absorption. Journal of the American College of Nutrition, 13, 584–591. doi:10.1080/07315724.1994.10718452

United States Census Bureau. (2017). Retrieved September 22, 2017, from https://www.census.gov/quickfacts/fact/table/US/PST045216

Valuck, R. J., & Ruscin, J. M. (2004). A case-control study on adverse effects: H2 blockers or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. Journal of Clinical Epidemiology, 57, 422–428. doi:10.1016/j.jclinepi.2003.08.015

Wolters, M., Strohle, A., & Hohn, A. (2004). Cobalamin: A critical vitamin in the elderly. Preventive Medicine, 39, 1256–1266. doi:10.1016/j.premed.2004.04.047

Valuck, R. J., Ruscin, J. M. (2004). A case-control study on adverse effects: H2 blockers or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. Journal of Clinical Epidemiology, 57, 422–428. doi:10.1016/j.jclinepi.2003.08.015

Wolters, M., Strohle, A., & Hohn, A. (2004). Cobalamin: A critical vitamin in the elderly. Preventive Medicine, 39, 1256–1266. doi:10.1016/j.premed.2004.04.047

World Health Organization. (2017). Overweight and Obesity. Retrieved September 22, 2017, from https://who.int/mediacentre/factsheets/fs311/en

Wu, J. C., Mui, L., Cheung, C. M., Chan, Y., & Jao-Yiu Sung, J. (2007). Obesity is associated with increased transient lower esophageal sphincter relaxation. Gastroenterology, 132, 883–889. doi:10.1053/j.gastro.2006.12.032

Yang, Y., & Metz, D. C. (2010). Safety of proton pump inhibitor exposure. Gastroenterology, 139, 1115–1127. doi:10.1053/j.gastro.2010.08.023